In a report released today, Chris Shibutani from Cowen & Co. maintained a Hold rating on Radius Health (RDUS). The company’s shares closed yesterday at $23.23.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.2% and a 40.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Pieris Pharmaceuticals, and Evelo Biosciences Inc.
Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $34.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.40 and a one-year low of $12.81. Currently, Radius Health has an average volume of 491.3K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.
